Journal Article

DKFZ-2023-02165

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.

Pouyiourou, M. (First author)DKFZ* ; Kraft, B. (First author)DKFZ* ; Wohlfromm, T.DKFZ* ; Stahl, M. ; Kubuschok, B. ; Löffler, H. ; Hacker, U. T. ; Hübner, G. ; Weiss, L. ; Bitzer, M. ; Ernst, T. ; Schütt, P. ; Hielscher, T.DKFZ* ; Delorme, S.DKFZ* ; Kirchner, M. ; Kazdal, D. ; Ball, M. ; Kluck, K. ; Stenzinger, A. ; Bochtler, T.DKFZ* ; Krämer, A. (Last author)DKFZ*

2023
Nature Publishing Group UK [London]

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41467-023-42400-5

Abstract: Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), patients relapsed or refractory after platinum-based chemotherapy received nivolumab and ipilimumab following TMBhigh vs. TMBlow stratification. Progression-free survival (PFS) represented the primary endpoint; overall survival (OS), response rates, duration of clinical benefit and safety were the secondary endpoints. The trial was prematurely terminated in March 2021 before reaching the preplanned sample size (n = 194). Among 31 evaluable patients, 16% had a high TMB ( > 12 mutations/Mb). Overall response rate was 16% (95% CI 6-34%), with 7.7% (95% CI 1-25%) vs. 60% (95% CI 15-95%) in TMBlow and TMBhigh, respectively. Although the primary endpoint was not met, high TMB was associated with better median PFS (18.3 vs. 2.4 months) and OS (18.3 vs. 3.6 months). Severe immune-related adverse events were reported in 29% of cases. Assessing on-treatment dynamics of circulating tumor DNA using combined targeted hotspot mutation and shallow whole genome sequencing as part of a predefined exploratory analysis identified patients benefiting from immunotherapy irrespective of initial radiologic response.

Note: #EA:A360#LA:A360#

---

Contributing Institute(s):

1. KKE Mol. Hämatologie/Onkologie (A360)
2. C060 Biostatistik (C060)
3. E010 Radiologie (E010)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2023

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Agriculture, Biology and Environmental Sciences ; Current Contents - Life Sciences ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 15 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record

---